Moderna's Executive Committee
- Stéphane Bancel, Chief Executive Officer
- Stephen Hoge, M.D., President
- Juan Andres, Chief Technical Operations and Quality Officer
- Paul Burton, M.D., Chief Medical Officer
- Kate Cronin, Chief Brand Officer
- Marcello Damiani, Chief Digital and Operational Excellence Officer
- Tracey Franklin, Chief Human Resources Officer
- Shannon Thyme Klinger, Chief Legal Officer and Corporate Secretary
- David Meline, Chief Financial Officer
Chief Executive Officer
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Stephen Hoge, M.D.
Stephen Hoge serves as the President of Moderna and leads all Research & Development for the company. Since Moderna’s early days, Dr. Hoge has led our scientific efforts, including the creation of our platform and therapeutic areas. More recently, he has assumed responsibility for the company’s Clinical Development Office. He joined Moderna in late 2012 from McKinsey & Company, where he was a partner in the healthcare practice. Prior to McKinsey, Dr. Hoge was a resident physician in New York City.
He holds an M.D. with thesis from the University of California, San Francisco, and a B.S. in neuroscience from Amherst College.
Currently, Dr. Hoge also serves on the Board of Directors of Axcella Health, Inc., a publicly traded, clinical-stage biotechnology company.
Chief Technical Operations and Quality Officer
As Chief Technical Operations and Quality Officer, Juan Andres is responsible for the supply of product required for Moderna’s preclinical and clinical development programs, as well as scaling the CMC (chemistry, manufacturing and controls) processes across Moderna’s portfolio. Mr. Andres also will lead all CMC late-stage development and future commercialization activities.
Mr. Andres was previously the Global Head of Technical Operations (Manufacturing and Supply Chain) for over 25,000 Novartis employees across all of its divisions. In this role, he had responsibility for all of Novartis’ manufacturing sites, and related support functions and technologies worldwide, overseeing small molecules drug substance and drug product, as well as biologics drug substance, drug product and technical development. Mr. Andres’ previous roles at Novartis included Group Novartis Quality Head, Global Head of Technical Research and Development, and Global Pharmaceutical Operations Head. Prior to Novartis, Mr. Andres worked at Eli Lilly & Co. for 18 years in a variety of manufacturing, production and quality roles in the United States, Puerto Rico, UK and Spain, most recently serving as Vice President, Pharmaceutical Manufacturing.
Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School.
Paul Burton, M.D., Ph.D., F.A.C.C, M.R.C.S
Chief Medical Officer
As Chief Medical Officer, Paul Burton oversees medical affairs and safety.
Dr. Burton joined Moderna after spending sixteen years with Johnson & Johnson. Since March 2020, he served as Chief Global Medical Affairs Officer of Janssen Pharmaceuticals where he was responsible for Janssen’s worldwide medical affairs strategy and execution. Previously, he served as Janssen’s Vice President and Head, Cardiovascular and Metabolic Medical Affairs. Dr. Burton also led the Johnson & Johnson collaboration with APPLE for the digital HEARTLINE™ study, and previously led clinical operations for all therapeutic areas across the Americas.
Dr. Burton has an M.D. from the University of London, is board certified in surgery and is a Member of the Royal College of Surgeons with specialist training in cardiothoracic surgery. He holds a Ph.D. in cardiovascular molecular and cellular biology from Imperial College in London and is a Fellow of the American College of Cardiology. He has published extensively in peer reviewed journals.
Chief Brand Officer
As Chief Brand Officer, Kate Cronin is responsible for amplifying Moderna’s story and the promise of mRNA science for patients.
Ms. Cronin joined Moderna from Ogilvy Health, part of WPP plc., where she served as Global CEO. In this role, she led the full spectrum of Ogilvy Health’s core capabilities including public relations and influence, brand strategy, advertising, medical education, market access, and patient and consumer engagement. Additionally, Ms. Cronin grew Ogilvy’s business in the health and wellness arena, encompassing a broad portfolio including pharmaceuticals, consumer health, insurance, hospitals, health technology and medical devices. Ms. Cronin led integrated campaigns involving social, digital, brand and public relations for Ogilvy’s largest, long-term health clients including BMS, Boehringer Ingelheim, Merck and Pfizer.
Prior to her role as CEO, Ms. Cronin held numerous leadership roles within Ogilvy including Global Managing Director, Managing Director of Ogilvy Public Relations’ New York office, and most recently Co-President of Ogilvy Health in the United States. Before her 17-year tenure at Ogilvy, Ms. Cronin was a Partner at Porter Novelli.
Before starting her career in communications, Ms. Cronin conducted research in the field of neurobiology at Cornell University Medical College. She coauthored several research articles focused on learning and memory and published in peer-review publications. Ms. Cronin received a Bachelor of Arts in biology from Smith College.
Chief Digital and Operational Excellence Officer
As Chief Digital and Operational Excellence Officer, Marcello Damiani brings a wealth of experience from both Tech companies and Life Science companies and a true passion for making Digital a reality. He has 20 years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and in the U.S.
Prior to joining Moderna, Mr. Damiani was instrumental in conceiving and building creative IT solutions to help solve business challenges, first at Motorola and then at bioMérieux. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company’s Information flow, and ultimately improving the product and the company’s processes through digitization.
Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and an international Executive MBA through TRIUM, an alliance of three of the world’s top universities: the London School of Economics, New York University’s Stern Business School, and the HEC School of Management in Paris.
Chief Human Resources Officer
As Chief Human Resources Officer, Tracey Franklin leads Moderna’s talent and organizational strategy.
Ms. Franklin joins Moderna following 15 years at Merck & Co., Inc. where she most recently led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer and served on Merck’s HR Leadership Team. In this role, Ms. Franklin was responsible for leading the vision, development and execution of the company’s Talent and Workforce Strategy with a focus on evolving the organizational culture and talent for the future. Ms. Franklin’s previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. She was based in Switzerland, the U.K. and the U.S.
Ms. Franklin holds a bachelor’s in communication arts and sciences from Pennsylvania State University and a master’s in industrial and organizational psychology from Fairleigh Dickinson University.
Shannon Thyme Klinger
Chief Legal Officer and Corporate Secretary
As chief legal officer and corporate secretary, Shannon Thyme Klinger leads Moderna’s legal, governance and corporate compliance efforts.
Ms. Klinger joined Moderna from Novartis (NYSE: NVS), where she served as Chief Legal Officer and a member of the Novartis Executive Committee since 2018. Previously, she served as Chief Ethics, Risk & Compliance Officer. During her ten-year tenure at Novartis, she held other roles of increasing responsibility, including as Chief Ethics and Compliance Officer and Global Head of Litigation, General Counsel and Global Head of Legal at Sandoz, a Novartis division.
Across her career, Ms. Klinger’s work has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, championing the responsible use of data, and enabling excellence in product launches. She is also a committed advocate for diversity, equity and inclusion.
Ms. Klinger served on the board of directors of the SIX Group in Switzerland from 2016 to 2020.
Ms. Klinger received her Juris Doctorate with honors from the University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame. She is a member of the State Bar of Georgia and the District of Columbia Bar.
Chief Financial Officer
As Chief Financial Officer, David Meline oversees financial, business development and business services functions at Moderna.
Mr. Meline previously served as Chief Financial Officer and EVP at Amgen from 2014 through 2019. At Amgen, he was responsible for all finance, information systems and global business services activities across 100 countries. In this role, Mr. Meline led enterprise-wide transformation while increasing growth and productivity and reducing development cycle time. Prior to Amgen, Mr. Meline spent six years at 3M Company, where he most recently served as CFO and Senior Vice President and was responsible for all 3M financial activities across 70 countries of operation. Previously, Mr. Meline held numerous leadership positions at General Motors, including Vice President and CFO for GM North America. During his tenure at GM, Mr. Meline lived and worked on five continents.
Mr. Meline received his Master of Business Administration in finance from the University of Chicago, his Master of Science in economics from the London School of Economics and his Bachelor of Science in mechanical engineering from Iowa State University.